// App-Quantinova.ai

: AN OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BLINATUMOMAB IN CHINESE ADULTS WITH RELAPSED/REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA

Researchers

Presenter

  • Hongsheng Zhou

Principal Investigators

  • Qingsong Yin

  • Jie Jin

  • Ting Liu

  • Zhen Cai

  • Bin Jiang

  • Dengju Li

  • Zimin Sun

  • Yan Li

  • Yanjuan He

  • Liping Ma

  • Yuqi Chen

  • Paul Gordon

  • Dong Yu

  • Gerhard Zugmaier

  • Jianxiang Wang

Medical Centers

  • Nanfang Hospital, Southern Medical University, Guangzhou, China

  • Henan Cancer Hospital, Zhengzhou, China

  • The FIrst Affiliated Hospital, College of Medicine, Zhejiang University, Zhejiang, China

  • West China Hospital of Sichua University, Chengdu, China

  • Peking University International Hospital, Beijing, China

  • Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

  • Anhui Provincial Hosp, Hefei, China

  • The Fist Affiliated Hospital of China Medical University, Shenyang, China

  • Xiangya Hospital Central South University, Changsha, China

  • Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

  • Global Biostatistical Science, Amgen Inc., Thousand Oaks, CA

  • Global Development, Amgen Inc. Thousand Oaks CA United States

  • China Development,Amgen China,Shanghai,China

  • Global Development,Amgen Research (Munich) GmbH,Munich,Germany

  • Institute of Hematology and Blood Diseases Hospital Peking Union Medical College,Beijing,China

Locations

  • China

  • United States

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Blinatumomab

Outcome

  • N/A

Study Design

  • Open Label

  • Single Arm

  • Multicenteric

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved